Changes to distribution relationship in North America
23 May 2023
Changes to distribution relationship in North America
Following a review of the North American (USA and Canada) probiotic ingredient market, a decision
has been made to consolidate our representation in this important market.
Since entering a strategic partnership and licensing agreement with Probi AB in July 2021, Blis has
been represented by both Stratum Nutrition and Probi AB for ingredient sales in North America. To
reduce the potential for customer confusion in market and drive efficiency in the supply chain to
support long term growth, the revised approach will be to work with Probi AB servicing existing
ingredient customers and securing new business.
Blis has worked with both parties to develop a transition plan to transfer existing customers and
leads to Probi and ensuring service levels and selling activity is maintained, with a handover date of
1 August 2023.
Blis has had a long standing, mutually beneficial distribution relationship with Stratum Nutrition. Blis
CEO Brian Watson said “We would like to acknowledge the positive contribution Stratum Nutrition
has made to our business in North America. The Stratum team have always been professional and a
pleasure to work with. This decision has been made to streamline our customer engagement in
market and set ourselves for longer term growth.”
Ends
For further information, please contact:
Brian Watson
CEO
+64 27 705 9133
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PEB — Pacific Edge Limited: Correction of LCD Reference Number2023-07-07
“6 July 2023 PACIFIC EDGE WELCOMES STAY OF NOVITAS LCD DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today welcomes a decision from Novitas 1 and First Coast to delay the implementation of the Local Coverage Determination (LCD, L393…”
- PEB — Pacific Edge Limited: Clarification of Novitas Timeline2023-06-01
“2 June 2023 CLARIFICATION OF NOVITAS TIMELINE DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today wishes to clarify the expected timeline for the finalization or withdrawal of the draft Local Coverage Determination (LCD) and the asso…”
- PEB — Pacific Edge Limited: Pacific Edge Welcomes Stay of Novitas LCD2023-07-05
“6 July 2023 PACIFIC EDGE WELCOMES STAY OF NOVITAS LCD DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today welcomes a decision from Novitas 1 and First Coast to delay the implementation of the Local Coverage Determination (LCD, L3…”